Schrodinger Inc
Change company Symbol lookup
Select an option...
SDGR Schrodinger Inc
SPLK Splunk Inc
TW Tradeweb Markets Inc
CMPGY Compass Group PLC
DZSI DZS Inc
FCPT Four Corners Property Trust Inc
UGI UGI Corp
BMI Badger Meter Inc
JKS JinkoSolar Holding Co Ltd
AGFY Agrify Corp
Go

Health Care : Health Care Technology | Small Cap Blend
Company profile

Schrodinger, Inc. has developed a physics-based software platform, which enables discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions and government laboratories around the world. The Company also leverages its software platform to advance collaborative programs and its own pipeline of therapeutics to address unmet medical needs. The Company operates through two segments: software and drug discovery. The software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on building a portfolio of preclinical and clinical programs, internally and through collaborations, which has advanced to various stages of discovery and development. The Company’s pipeline of drug discovery programs include MALT1, CDC7, Wee1, and SOS1/KRAS.

Postmarket

Last Trade
Delayed
$26.86
0.73 (2.79%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$26.13
Day's Change
-1.48 (-5.36%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
27.51
Day's Low
25.87
Volume
(Heavy Day)
Volume:
801,428

10-day average volume:
561,384
801,428

Schrodinger to Present at Piper Sandler 34th Annual Healthcare Conference

8:30 am ET November 21, 2022 (BusinessWire) Print

Schrodinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The presentation will take place on Tuesday, November 29, 2022, at 4:00 p.m. ET.

The live discussion can be accessed under "News & Events" in the investors section of Schrodinger's website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.

About Schrodinger

Schrodinger is transforming the way therapeutics and materials are discovered. Schrodinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrodinger's multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrodinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, and Instagram or visit our blog, Extrapolations.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005015/en/

SOURCE: Schrodinger

Jaren Irene Madden
jaren.madden@schrodinger.com 
617-286-6264
comtex tracking

COMTEX_419397380/1006/2022-11-21T08:30:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.